透雲生物(01332.HK)擬1300萬元出售威道國際70%股權
格隆匯5月6日丨透雲生物(01332.HK)公吿,於2025年5月6日,賣方(公司的直接全資附屬公司)與買方復興國際中國有限公司已訂立出售協議,據此,賣方已有條件同意出售而買方已有條件同意購買待售股份,其相當於目標公司威道國際有限公司股份總數的70%,代價為人民幣1300萬元。
目標公司為一間於香港註冊成立的有限公司,主要從事提供產品包裝上的二維碼及解決方案以及廣吿展示服務。於本公吿日期,目標公司由賣方及買方分別擁有70%及30%權益。
儘管目標公司於2024年12月31日錄得未經審核負債淨額約2,000,000港元,但買方經審閲目標公司的業務及營運狀況後,對其未來財務表現仍然樂觀。經計及集團將收取的代價,董事會認為集團進行出售事項乃屬恰當。出售事項落實後,可消除目標公司帶來的負債增加的風險,並加強集團的現金流,讓集團改善其流動性,並讓集團得以重新配置其資源用於未來發展。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.